Extended Release Injectable Drugs Research Report 2023: Formulation Technologies & Platforms, Physical Process Control Methods, Development Factors, Competitive Landscape

News provided by

Jun 16, 2023, 18:30 ET

DUBLIN, June 16, 2023 /PRNewswire/ -- The "Extended Release Injectable Drugs" report has been added to ResearchAndMarkets.com's offering.

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases.

For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles.

These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to produce APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.

Key Topics Covered:

1. Executive Summary

2. Injectable Drug Market Dynamics

The Trend toward Self-Administration

3. Injectable Drug Formulation Technology

Innovation in Injectable Device Designs
Therapeutic Demand Drivers

4. Market Factors

Patient Compliance and Ease of Use
Healthcare Regulations
Managed Care Initiatives
Competitive Landscape
Risk Factors

5. Extended-release Formulation Technologies

Biodegradable Polymers
PEG
PLA/PLGA
Polyether ester

6. Extended-release Formulation Platforms

BEPO (MedinCell)
ChroniJect (Oakwood Laboratories/PharmaSophia)
CriticalMix (Critical Pharmaceuticals)
Depofoam (Pacira)
FluidCrystal (Camarus)
LinkeRx (Alkermes)
Medisorb (Alkermes)
Medusa (Recipharm/Avadel)
Nanocrystals (Alkermes)
Optisomes (Talon/Spectrum)
PolyActive (Octoplus)
Q-Sphera (Midatech Pharma)
SABER/SAIB (DURECT)
SynBiosys (Innocore)
TransCon (Ascendis)

7. Physical Process Control Methods

Supercritical Fluid
SCF for Nanoparticle Formulations
Formulplex (Supercritical Solutions)
Ferro
SCF extraction of emulsions (SFEE)

8. Extended-release Injectables - Development Factors

Formulation Factors
Stability
Administration Factors

9. Extended Release Injectables - Product Analysis

Aripiprazole
Aripiprazole lauroxil
Bupivacaine
Buprenorphine
Cytarabine
Cytarabine & Daunorubicin
Doxorubicin
Estradiol
Exenatide
Fluphenazine decanoate
Goserelin acetate
Granisetron
Interferon
Irinotecan
Lanreotide acetate
Leuprolide
Leuprolide Depot
Medroxyprogesterone
Naltrexone
Octreotide acetate
Olanzapine Pamoate
Paliperidone palmitate
Pasireotide
Pegvaliase-pqpz
Risperidone
Testosterone
Triptorelin
Triamcinolone acetonide
Vincristine sulfate
Glycemic Control
AB101 (Rezolute)
Hormone Deficiency
Human Growth Hormone/Ascendis
Addiction
CAM2038 (Camurus)
Pain Management
Posidur/Durect
Cardiology
Treprostinil/Ascendis Pharma
Neurology
Relday/Risperidone (DURECT/Zogenix)
Oncology
CAM2032 (Camurus)

10. Extended-Release Injectables - Selected Sector Analysis

Addiction
Glycemic Control
Infectious Disease
Hepatitis
Neurology
Schizophrenia
Bipolar Disorder
Oncology
Pain Management
Reproductive Health
Fertility
Endometriosis
Vasomotor Symptoms associated with Menopause

11. Company Profiles

Alkermes
Amylin
AntriaBio
Ascendis Pharma
AstraZeneca
Aurobundo
Avadel
Biomarin
Camurus
Critical Pharmaceuticals
DURECT
Eli Lilly
Enzon
Ipsen
Janssen
NanOlogy
Novartis
OctoPlus
Oakwood Laboratories/PharmaSophia
Pacira
PhaseBio Pharmaceuticals
Recipharm AB
Roche
Sanofi
Taiwan Liposome Company (TLC)
Xbrane Bipharma

For more information about this report visit https://www.researchandmarkets.com/r/wbugpj

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets